- Home
- SWBI vs CLLS Comparison
SWBI vs CLLS Comparison
Compare SWBI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWBI | CLLS |
|---|---|---|
| Founded | 1852 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.6M | 485.6M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | SWBI | CLLS |
|---|---|---|
| Price | $9.99 | $4.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $11.00 | $8.50 |
| AVG Volume (30 Days) | ★ 794.9K | 112.6K |
| Earning Date | 12-04-2025 | 11-07-2025 |
| Dividend Yield | ★ 5.21% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $466,396,000.00 | $82,551,000.00 |
| Revenue This Year | $2.62 | $32.58 |
| Revenue Next Year | $3.23 | $20.68 |
| P/E Ratio | $47.77 | ★ N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $7.73 | $1.10 |
| 52 Week High | $11.50 | $5.48 |
Technical Indicators
Market Signals| Indicator | SWBI | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 54.48 |
| Support Level | $10.62 | $4.47 |
| Resistance Level | $10.49 | $5.03 |
| Average True Range (ATR) | 0.31 | 0.28 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 3.55 | 54.55 |
Price Performance
Historical ComparisonAbout SWBI Smith & Wesson Brands Inc.
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.